Stupp, Roger; Hegi, Monika E; Neyns, Bart; Goldbrunner, Roland; Schlegel, Uwe; Clement, Paul M J; Grabenbauer, Gerhard G; Ochsenbein, Adrian F; Simon, Matthias; Dietrich, Pierre-Yves; Pietsch, Torsten; Hicking, Christine; Tonn, Joerg-Christian; Diserens, Annie-Claire; Pica, Alessia; Hermisson, Mirjam; Krueger, Stefan; Picard, Martin; Weller, Michael (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of clinical oncology, 28(16), pp. 2712-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2009.26.6650
Full text not available from this repository. (Request a copy)Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology |
UniBE Contributor: |
Ochsenbein, Adrian, Pica, Alessia |
ISSN: |
0732-183X |
Publisher: |
American Society of Clinical Oncology |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:09 |
Last Modified: |
05 Dec 2022 14:00 |
Publisher DOI: |
10.1200/JCO.2009.26.6650 |
PubMed ID: |
20439646 |
Web of Science ID: |
000278108800010 |
URI: |
https://boris.unibe.ch/id/eprint/1061 (FactScience: 201786) |
Actions (login required)
 |
Edit item |